Opinion

Video

Current Landscape of Bispecific Therapies for RRMM

Key Takeaways

  • Bispecific therapies target both tumor antigens and T-cell receptors, enhancing immune responses against myeloma cells in RRMM.
  • Several bispecific antibodies are approved or in clinical trials, showing promise in overcoming resistance to conventional therapies.
SHOW MORE

Panelists discuss how bispecific T-cell–engaging therapies targeting BCMA, GPRC5D, and FcRH5 have emerged as novel immunotherapeutic approaches showing meaningful clinical activity for patients with heavily pretreated relapsed/refractory multiple

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
1 KOL is featured in this series.
1 expert in this video